MovDisordV3, Main, Merge, bibRecord, 002745

Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study

Identifieur interne : 002745 ( Main/Merge ); précédent : 002744; suivant : 002746

Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study

Auteurs : Yoshikuni Mizuno [Japon] ; Kazuko Hasegawa [Japon] ; Tomoyoshi Kondo [Japon] ; Sadako Kuno [Japon] ; Mitsutoshi Yamamoto [Japon]

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0377340

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Istradéfylline, Adénosine, Lévodopa.

English descriptors

KwdEn :
- Adenosine, Istradefylline, Levodopa, Nervous system diseases, Parkinson disease.

Abstract

The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose or 20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor complications on levodopa therapy based on the change in the daily OFF time compared with placebo and to assess the safety at these doses. A total of 363 subjects were randomly assigned to receive 20 mg/day istradefylline (n = 119), 40 mg/day istradefylline (n = 125), or placebo (n = 119). The primary outcome variable was the change from baseline at endpoint in daily OFF time based on patients' ON/OFF diaries. At endpoint, the daily OFF time reduced from baseline by 1.31 hours for 20 mg/day istradefylline (P = 0.013 as compared to the placebo), 1.58 hours for 40 mg/ day istradefylline (P < 0.001), and 0.66 hours for placebo; istradefylline significantly reduced the daily OFF time compared with placebo. The UPDRS Part III subscale score (ON state) reduced by 5.7 at endpoint in both istradefylline groups and 3.7 in the placebo group (P = 0.006 for 20 mg/day and P = 0.006 for 40 mg/day group as compared with placebo). The most commonly reported drug-related treatment emergent adverse event (TEAE) was dyskinesia, which occurred in 2.5% (3/119) of subjects receiving placebo, 8.5% (10/118) receiving 20 mg/day istradefylline, and 6.4% (8/125) receiving 40 mg/day istradefylline. We conclude that istradefy line at 20 mg and 40 mg once daily is effective in relieving wearing-off fluctuations of PD patients. In addition, istradefy line was well tolerated at both doses.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000998
to stream PascalFrancis, to step Curation: 002321
to stream PascalFrancis, to step Checkpoint: 000B58

Links to Exploration step

Pascal:10-0377340

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study</title>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, Research Institute for Diseases of Old Age, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, National Hospital Organization Sagamihara National Hospital</s1>
<s2>Kanagawa</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kanagawa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Wakayama Medical University Hospital</s1>
<s2>Wakayama</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Wakayama</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Neurology, National Center of Neurology and Psychiatry</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Kagawa Prefectural Central Hospital</s1>
<s2>Kagawa</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kagawa</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0377340</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0377340 INIST</idno>
<idno type="RBID">Pascal:10-0377340</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000998</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002321</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000B58</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Mizuno Y:clinical:efficacy:of</idno>
<idno type="wicri:Area/Main/Merge">002745</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study</title>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, Research Institute for Diseases of Old Age, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, National Hospital Organization Sagamihara National Hospital</s1>
<s2>Kanagawa</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kanagawa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Wakayama Medical University Hospital</s1>
<s2>Wakayama</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Wakayama</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Neurology, National Center of Neurology and Psychiatry</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Kagawa Prefectural Central Hospital</s1>
<s2>Kagawa</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kagawa</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine</term>
<term>Istradefylline</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Istradéfylline</term>
<term>Adénosine</term>
<term>Lévodopa</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose or 20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor complications on levodopa therapy based on the change in the daily OFF time compared with placebo and to assess the safety at these doses. A total of 363 subjects were randomly assigned to receive 20 mg/day istradefylline (n = 119), 40 mg/day istradefylline (n = 125), or placebo (n = 119). The primary outcome variable was the change from baseline at endpoint in daily OFF time based on patients' ON/OFF diaries. At endpoint, the daily OFF time reduced from baseline by 1.31 hours for 20 mg/day istradefylline (P = 0.013 as compared to the placebo), 1.58 hours for 40 mg/ day istradefylline (P < 0.001), and 0.66 hours for placebo; istradefylline significantly reduced the daily OFF time compared with placebo. The UPDRS Part III subscale score (ON state) reduced by 5.7 at endpoint in both istradefylline groups and 3.7 in the placebo group (P = 0.006 for 20 mg/day and P = 0.006 for 40 mg/day group as compared with placebo). The most commonly reported drug-related treatment emergent adverse event (TEAE) was dyskinesia, which occurred in 2.5% (3/119) of subjects receiving placebo, 8.5% (10/118) receiving 20 mg/day istradefylline, and 6.4% (8/125) receiving 40 mg/day istradefylline. We conclude that istradefy line at 20 mg and 40 mg once daily is effective in relieving wearing-off fluctuations of PD patients. In addition, istradefy line was well tolerated at both doses.</div>
</front>
</TEI>
<affiliations><list><country><li>Japon</li>
</country>
<settlement><li>Tokyo</li>
</settlement>
</list>
<tree><country name="Japon"><noRegion><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
</noRegion>
<name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name>
<name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name>
<name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name>
<name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002745 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002745 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:10-0377340
   |texte=   Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study

Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri